These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34769222)

  • 1. Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice.
    Hoffmann T; Rahfeld JU; Schenk M; Ponath F; Makioka K; Hutter-Paier B; Lues I; Lemere CA; Schilling S
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the binding mode of PQ912 against secretory glutaminyl cyclase through systematic exploitation of conformational ensembles.
    Chandran R; Dileep KV
    Chem Biol Drug Des; 2021 Nov; 98(5):850-856. PubMed ID: 34423556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy.
    Hoffmann T; Meyer A; Heiser U; Kurat S; Böhme L; Kleinschmidt M; Bühring KU; Hutter-Paier B; Farcher M; Demuth HU; Lues I; Schilling S
    J Pharmacol Exp Ther; 2017 Jul; 362(1):119-130. PubMed ID: 28446518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design.
    Van Manh N; Hoang VH; Ngo VTH; Ann J; Jang TH; Ha JH; Song JY; Ha HJ; Kim H; Kim YH; Lee J; Lee J
    Eur J Med Chem; 2021 Dec; 226():113819. PubMed ID: 34536669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation.
    Hettmann T; Gillies SD; Kleinschmidt M; Piechotta A; Makioka K; Lemere CA; Schilling S; Rahfeld JU; Lues I
    Sci Rep; 2020 Feb; 10(1):3294. PubMed ID: 32094456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
    Schilling S; Zeitschel U; Hoffmann T; Heiser U; Francke M; Kehlen A; Holzer M; Hutter-Paier B; Prokesch M; Windisch M; Jagla W; Schlenzig D; Lindner C; Rudolph T; Reuter G; Cynis H; Montag D; Demuth HU; Rossner S
    Nat Med; 2008 Oct; 14(10):1106-11. PubMed ID: 18836460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells.
    Cynis H; Schilling S; Bodnár M; Hoffmann T; Heiser U; Saido TC; Demuth HU
    Biochim Biophys Acta; 2006 Oct; 1764(10):1618-25. PubMed ID: 17005457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta.
    Cynis H; Scheel E; Saido TC; Schilling S; Demuth HU
    Biochemistry; 2008 Jul; 47(28):7405-13. PubMed ID: 18570439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel monoclonal antibody 3B8 specifically recognizes pyroglutamate-modified amyloid β 3-42 peptide in brain of AD patients and 3xTg-AD transgenic mice.
    Acero G; Garay C; Venegas D; Ortega E; Gevorkian G
    Neurosci Lett; 2020 Apr; 724():134876. PubMed ID: 32114116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.
    Hartlage-Rübsamen M; Bluhm A; Piechotta A; Linnert M; Rahfeld JU; Demuth HU; Lues I; Kuhn PH; Lichtenthaler SF; Roßner S; Höfling C
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29673150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
    Hartlage-Rübsamen M; Morawski M; Waniek A; Jäger C; Zeitschel U; Koch B; Cynis H; Schilling S; Schliebs R; Demuth HU; Rossner S
    Acta Neuropathol; 2011 Jun; 121(6):705-19. PubMed ID: 21301857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of glutaminyl cyclase inhibitors for Alzheimer's disease.
    Coimbra JR; Sobral PJ; Santos AE; Moreira PI; Salvador JA
    Future Med Chem; 2019 Dec; 11(24):3179-3194. PubMed ID: 31838899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl-Peptidase Activity of Meprin β Links N-truncation of Aβ with Glutaminyl Cyclase-Catalyzed pGlu-Aβ Formation.
    Schlenzig D; Cynis H; Hartlage-Rübsamen M; Zeitschel U; Menge K; Fothe A; Ramsbeck D; Spahn C; Wermann M; Roßner S; Buchholz M; Schilling S; Demuth HU
    J Alzheimers Dis; 2018; 66(1):359-375. PubMed ID: 30320570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology.
    Gnoth K; Piechotta A; Kleinschmidt M; Konrath S; Schenk M; Taudte N; Ramsbeck D; Rieckmann V; Geissler S; Eichentopf R; Barendrecht S; Hartlage-Rübsamen M; Demuth HU; Roßner S; Cynis H; Rahfeld JU; Schilling S
    Alzheimers Res Ther; 2020 Nov; 12(1):149. PubMed ID: 33189132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
    Morawski M; Schilling S; Kreuzberger M; Waniek A; Jäger C; Koch B; Cynis H; Kehlen A; Arendt T; Hartlage-Rübsamen M; Demuth HU; Roßner S
    J Alzheimers Dis; 2014; 39(2):385-400. PubMed ID: 24164736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focused ultrasound with anti-pGlu3 Aβ enhances efficacy in Alzheimer's disease-like mice via recruitment of peripheral immune cells.
    Sun T; Shi Q; Zhang Y; Power C; Hoesch C; Antonelli S; Schroeder MK; Caldarone BJ; Taudte N; Schenk M; Hettmann T; Schilling S; McDannold NJ; Lemere CA
    J Control Release; 2021 Aug; 336():443-456. PubMed ID: 34186148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concerted action of dipeptidyl peptidase IV and glutaminyl cyclase results in formation of pyroglutamate-modified amyloid peptides in vitro.
    Antonyan A; Schlenzig D; Schilling S; Naumann M; Sharoyan S; Mardanyan S; Demuth HU
    Neurochem Int; 2018 Feb; 113():112-119. PubMed ID: 29224965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.
    Hook G; Yu J; Toneff T; Kindy M; Hook V
    J Alzheimers Dis; 2014; 41(1):129-49. PubMed ID: 24595198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of glutaminyl cyclase ameliorates amyloid pathology in an animal model of Alzheimer's disease via the modulation of γ-secretase activity.
    Song H; Chang YJ; Moon M; Park SK; Tran PT; Hoang VH; Lee J; Mook-Jung I
    J Alzheimers Dis; 2015; 43(3):797-807. PubMed ID: 25114069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer's Agents Based on Rational Design.
    Hoang VH; Tran PT; Cui M; Ngo VT; Ann J; Park J; Lee J; Choi K; Cho H; Kim H; Ha HJ; Hong HS; Choi S; Kim YH; Lee J
    J Med Chem; 2017 Mar; 60(6):2573-2590. PubMed ID: 28234463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.